^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for recurrent glioblastoma patients

Published date:
11/16/2020
Excerpt:
Eighty bevacizumab-naive, recurrent glioblastoma patients randomized to pembrolizumab with bevacizumab (cohort A, n=50) or pembrolizumab monotherapy (cohort B, n=30)….Tumor immune markers were not associated with OS, but worsened OS correlated with baseline dexamethasone use and increased post-therapy plasma VEGF (cohort A) and mutant IDH1, unmethylated MGMT and increased baseline PlGF and sVEGFR1 levels (cohort B)...Pembrolizumab was ineffective as monotherapy and with bevacizumab for recurrent glioblastoma.
DOI:
10.1158/1078-0432.CCR-20-2500